C
Cassandra M. Skinner
Publications - 4
Citations - 340
Cassandra M. Skinner is an academic researcher. The author has contributed to research in topics: Ixekizumab & Medicine. The author has an hindex of 2, co-authored 2 publications receiving 206 citations.
Papers
More filters
Journal ArticleDOI
Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial
Désirée van der Heijde,James Cheng-Chung Wei,Maxime Dougados,Philip J. Mease,Atul Deodhar,Walter P. Maksymowych,Filip Van den Bosch,Joachim Sieper,Tetsuya Tomita,Robert Landewé,Fangyi Zhao,Eswar Krishnan,David H. Adams,Beth A. Pangallo,Hilde Carlier,Melvin Churchill,Kathleen P. Flint,Geoffrey Gladstein,Maria Greenwald,Mary P. Howell,Akgun Ince,Jeffrey L. Kaine,Daksha Mehta,Eric A. Peters,Roel Querubin,John D. Reveille,Richard Roseff,Roger J. Diegel,Christine Thai,Louis Bessette,Frederic Morin,Proton Rahman,Aaron Alejandro Barrera Rodriguez,Fidencio Cons-Molina,Sergio Duran Barragan,Cassandra M. Skinner,Cesar Francisco Pacheco Tena,Cesar Ricardo Ramos Remus,Juan Cruz Rizo Rodriguez,Seung-Jae Hong,Yeon-Ah Lee,Ji Hyeon Ju,Seong Wook Kang,Tae-Hwan Kim,Chang Keun Lee,Eun Bong Lee,Sang-Heon Lee,Min Chan Park,Kichul Shin,Sang-Hoon Lee,Hung-An Chen,Ying-Chou Chen,Song-Chou Hsieh,Joung-Liang Lan,Zdenek Dvorak,Radka Moravcova,Martina Malcova,Yoshinori Taniguchi,Mitsumasa Kishimoto,Kurisu Tada,Hiroaki Dobashi,Kentaro Inui,Yukitaka Ueki,Yoshifuji Matsumoto,Yoshinobu Koyama,Kazuhiro Hatta,Tatsuya Atsumi,Hitoshi Goto,Kiyoshi Matsui,Yuya Takakubo,Gunther Neeck,Denis Poddubnyy,Andrea Rubbert-Roth,Malgorzata Szymanska,Tomasz Blicharski,Anna Dudek,Artur Racewicz,Rafal Wojciechowski,Marleen G H van de Sande,Ed Griep,Michael T. Nurmohamed,Galina Matsievskaya,Evgeniya Shmidt,Marina Stanislav,Sergey Yakushin,Olga Ershova,A P Rebrov,Tibor Balazs,Regina Cseuz,E. Drescher,Gyula Poor +90 more
TL;DR: Each dosing regimen of ixekizumab was superior to placebo for improving radiographic axial spondyloarthritis signs and symptoms in patients not previously treated with bDMARDs; the safety profile was consistent with previous indications of IXekzumab.
Journal ArticleDOI
Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial
Atul Deodhar,Désirée van der Heijde,Lianne S. Gensler,Tae-Hwan Kim,Walter P. Maksymowych,Mikkel Østergaard,Denis Poddubnyy,Helena Marzo-Ortega,Helena Marzo-Ortega,Louis Bessette,Tetsuya Tomita,Ann Leung,M. Hojnik,Gaia Gallo,Xiaoqi Li,David H. Adams,Hilde Carlier,Joachim Sieper,Frederic Morin,Proton Rahman,Federico Ariel,Alberto Berman,Judith Carrio,Eleonora Lucero,Jose Maldonado Cocco,Rodolfo A Pardo Hidalgo,Jorge Velasco,Diego O. Viola,Johannes Grisar,Heinrich Resch,Clemens Scheinecker,Ana Claudia Melazzi,Luis Roimicher,Antonio Scafuto Scotton,Aaron Alejandro Barrera Rodriguez,Francisco Fidencio Cons Molina,Sergio Duran Barragan,Cassandra M. Skinner,Cesar Francisco Pacheco Tena,Cesar Ricardo Ramos Remus,Juan Cruz Rizo Rodriguez,Seung Jae Hong,Seong Wook Kang,Chang Keun Lee,Eun Bong Lee,Sang-Heon Lee,Min Chan Park,Sang-Hoon Lee,Eva Dokoupilova,Zdenek Dvorak,Martina Malcova,Karel Pvelka,Kari K. Eklund,Pentti Jarvinen,Anna Karjalainen,Leena Paimela,Yoshinori Taniguchi,Tokutaro Tsuda,Kurisu Tada,Hiroaki Dobashi,Kentaro Inui,Yukitaka Ueki,Yoshifuji Matsumoto,Kazuhiro Hatta,Tatsuya Atsumi,Hitoshi Goto,Shigeru Honjo,Kiyoshi Matsui,Yuya Takakubo,Gunther Neeck,Sylke Wagner,Jürgen Braun,Tomasz Blicharshi,Anna Dudek,Pawel Hrycai,Rafal Plebanski,Janina Drabiszcak-Piatkowska,Jan Brzezicki,Marek Krogulec,Daniela Opris-Belinski,Ana Maria Ramazan,Luminita Tronaru,Marleen G H van de Sande,Galina Matsievskaya,Evgeniya Schmidt,Marina Stanislav,Sergey Yakushin,Olga Ershova,Andrey Rebroy,Melvin Churchill,Kathleen P. Flint,Maria Greenwald,Mary P. Howell,Jeffrey L. Kaine,Alan Kivitz,Steven J. Klein,Eric C. Mueller,Eric A. Peters,Roel Querubin,Michael E. Sayers,Craig D. Scoville,Joseph C. Shanahan,Richard Roseff,John E. Hull,Jyothi R. Mallepalli,Mohamed B. Sebai,Steven C. Kimmel,David H. Goddard,Philip J. Mease,Mark D. Harris,Arthur R. Mabaquiao,Roger J. Diegel,Christine Thai,Tania L. Rivera,Amarilis Perez-De Jesus,Oscar Soto-Raices,Ramon Toro-Torres,Carlos Pantojas +117 more
TL;DR: Ixekizumab was superior to placebo for improving signs and symptoms in patients with non-radiographic axial spondyloarthritis and no new safety signals were identified.
Journal ArticleDOI
Comparative Metastatic Rates in GEP Class 1A versus 1B Posterior Uveal Melanoma: Results Contrary to Expectations
TL;DR: In this paper , the authors determined whether the metastatic rates in patients with gene expression profile (GEP) class 1A versus 1B posterior uveal malignant melanoma supported or contradicted predictions of very low metastatic rate in GEP 1A cases and moderate rate in gep 1B cases.
Journal ArticleDOI
Response to Cook and Alsina’s Letter to Editor
TL;DR: In this paper , the authors present a letter and does not have abstract, but it is a letter written by the author and it is abstracted from the original abstracts of the paper.